Treatment options for multiple sclerosis (MS) are limited. The immunomodulatory drugs interferon beta and glatiramer acetate are only partly effective in reducing the relapse rate, slowing disease progression, and diminishing the number and volume of lesions on I. MRMitoxantrone is an immunosuppressant ...
New diagnostic and therapeutic options for the treatment of multiple sclerosis Clinical Applications of Immunomics 2009;2:205-26.Riccio P, Haas H, Liuzzi GM, Rossano R. New diagnostic and therapeutic options for the treatment of multiple sclerosis. Clinical Applications of Immunomics. 2009; 2 :...
There are several treatment options for multiple sclerosis. The examples listed below are U.S. FDA-approved drugs to treat multiple sclerosis. These are known as disease-modifying therapies for MS. Disease-modifying therapies have been found through clinical trials to reduce the number of relapses,...
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the diseas...
Monoclonal antibodies (MAbs) may have great potential as therapies for autoimmune diseases. Their development as treatments for multiple sclerosis (MS) is promising. Partially effective immunomodulatory therapies have been helpful for many MS patients; however, for patients failing these immunomodulatory tre...
Treatment of Multiple Sclerosis 作者:Rudick, Richard A.; Goodkin, Donald E.; 副标题:Trial Design, Results and Future Perspectives 页数:313 ISBN:9783540196839 豆瓣评分 目前无人评价 评价: 写笔记 写书评 加入购书单 分享到 推荐
Furthermore, options for possible therapeutic intervention through the chemokine system are outlined. Clinical studies in MS patients applying this knowledge are expected soon. 展开 关键词: Chemokine Chemokinrezeptorantagonisten Multiple Sklerose Chemokine Chemokine receptor antagonist Multiple sclerosis ...
Multiple sclerosis: Immunotherapy Current Treatment Options in NeurologyBielekova B, Martin R. 1999. Multiple sclerosis: immunotherapy. Curr. Treat. Options Neurol. 1: 201... B Bielekova,R Martin - 《Current Treatment Options in Neurology》 被引量: 65发表: 1999年 Primary Progressive Multiple Scl...
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial Compared with other countries, patients with chronic hepatitis C infection in Japan...
Therapies for relapsing-remitting pediatric multiple sclerosis (MS) are aimed at preventing relapses (disease modifying therapies), treating acute attacks,